Academic Journal

Treatment and overall survival of four types of non-metastatic periampullary cancer:nationwide population-based cohort study

التفاصيل البيبلوغرافية
العنوان: Treatment and overall survival of four types of non-metastatic periampullary cancer:nationwide population-based cohort study
المؤلفون: de Jong, Evelien J M, van der Geest, Lydia G, Besselink, Marc G, Bouwense, Stefan A W, Buijsen, Jeroen, Dejong, C H C, Koerkamp, Bas G, Heij, Lara R, de Hingh, Ignace H J T, Hoge, Chantal, Kazemier, Geert, van Laarhoven, Hanneke W M, de Meijer, Vincent E, Stommel, Martijn W J, Tjan-Heijnen, Vivianne C G, Valkenburg-van Iersel, Liselot B J, Wilmink, Johanna W, Geurts, Sandra M E, de Vos-Geelen, Judith
المصدر: Dutch Pancreatic Cancer Group , de Jong , E J M , van der Geest , L G , Besselink , M G , Bouwense , S A W , Buijsen , J , Dejong , C H C , Koerkamp , B G , Heij , L R , de Hingh , I H J T , Hoge , C , Kazemier , G , van Laarhoven , H W M , de Meijer , V E , Stommel , M W J , Tjan-Heijnen , V C G , Valkenburg-van Iersel , L B J , Wilmink ....
سنة النشر: 2022
المجموعة: University of Groningen research database
الوصف: BACKGROUND: Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (DA). The aim of this study was to assess treatment modalities and overall survival by tumor origin. METHODS: Patients diagnosed with non-metastatic periampullary cancer in 2012-2018 were identified from the Netherlands Cancer Registry. OS was studied with Kaplan-Meier analysis and multivariable Cox regression analyses, stratified by origin. RESULTS: Among the 8758 patients included, 68% had PDAC, 13% DC, 12% AC, and 7% DA. Resection was performed in 35% of PDAC, 56% of DC, 70% of AC, and 59% of DA. Neoadjuvant and/or adjuvant therapy was administered in 22% of PDAC, 7% of DC, 7% of AC, and 12% of DA. Three-year OS was highest for AC (37%) and DA (34%), followed by DC (21%) and PDAC (11%). Adjuvant therapy was associated with improved OS among PDAC (HR = 0.62; 95% CI 0.55-0.69) and DC (HR = 0.69; 95% CI 0.48-0.98), but not AC (HR = 0.87; 95% CI 0.62-1.22) and DA (HR = 0.85; 95% CI 0.48-1.50). CONCLUSION: This retrospective study identified considerable differences in treatment modalities and OS between the four periampullary cancer origins in daily clinical practice. An improved OS after adjuvant chemotherapy could not be demonstrated in patients with AC and DA.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
DOI: 10.1016/j.hpb.2022.01.009
الاتاحة: https://hdl.handle.net/11370/f699f96e-e062-4664-94c7-9f61406f7838
https://research.rug.nl/en/publications/f699f96e-e062-4664-94c7-9f61406f7838
https://doi.org/10.1016/j.hpb.2022.01.009
https://pure.rug.nl/ws/files/245838953/1_s2.0_S1365182X22000442_main.pdf
Rights: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.E8005CAA
قاعدة البيانات: BASE
الوصف
DOI:10.1016/j.hpb.2022.01.009